Citations 1497

IC‐P‐151: Longitudinal outcomes and profiles of distinct biomarker clusters based on vascular disease, neurodegeneration, and amyloid deposition

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2015.06.174

P1‐049: Exploiting blood transcriptome for gene and pathway identification in Alzheimer's disease

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2015.06.245

P2‐015: Exploring alternative splicing and gene expression of load candidate genes in blood

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2015.06.551

IC‐04‐04: Optimizing PiB‐PET change‐over‐time measurement by analysis of longitudinal reliability, plausibility, and separability

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2015.06.018

IC‐P‐061: Frequency and distribution of cerebral microbleeds in dementia with lewy bodies

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2015.06.082

O2‐09‐03: Evidence of reduced neuronal plasticity to education in ApoE‐ɛ4 carriers

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2015.07.179

P4‐053: Memory, executive, and multi‐domain subtle cognitive impairment: Clinical and biomarker finding

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2015.06.1758

Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer’s Disease: A Diffusion Tensor Imaging Study

Journal of Alzheimer's Disease | December 14, 2015 | Volume: 49 | Issue: 3 | Pages: 633-643

10.3233/jad-150502 | PMID 26484918

Background: Different clinical syndromes can arise from Alzheimer’s disease (AD) neuropathology, including dementia of the Alzheimer’s type (DAT), logopenic primary progressive aphasia (lvPPA), and posterior cortical atrophy (PCA). Objective: To assess similarities and differences in patterns of white matter tract degeneration across these syndromic variants of AD. Methods: Sixty-four subjects (22 DAT, 24 lvPPA, and 18 PCA) that had diffusion tensor imaging and showed amyloid-β deposition on PET were assessed in this case-control study. A whole-brain voxel-based analysis was performed to assess differences in fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity across groups. Results: All three groups showed overlapping diffusion abnormalities in a network of tracts, including fornix, corpus callosum, posterior thalamic radiations, superior longitudinal fasciculus, inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, and uncinate fasciculus. Subtle regional differences were also observed across groups, with DAT particularly associated with degeneration of fornix and cingulum, lvPPA with left inferior fronto-occipital fasciculus and uncinate fasciculus, and PCA with posterior thalamic radiations, superior longitudinal fasciculus, posterior cingulate, and splenium of the corpus callosum. Conclusion: These findings show that while each AD phenotype is associated with degeneration of a specific structural network of white matter tracts, striking spatial overlap exists among the three network patterns that may be related to AD pathology.
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

JAMA Neurology | November 23, 2015 | Volume: 73 | Issue: 1 | Pages: 85

10.1001/jamaneurol.2015.3098 | PMID 26595683

Influence of amyloid and APOE on cognitive performance in a late middle‐aged cohort

Alzheimer's & Dementia | November 19, 2015 | Volume: 12 | Issue: 3 | Pages: 281-291

10.1016/j.jalz.2015.09.010 | PMID 26602629

AbstractIntroductionFew studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle‐aged individuals.MethodsWe included 464 cognitively normal, test‐naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51–71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow‐up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline.ResultsElevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE ɛ4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test.DiscussionElevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.